Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

RBC Capital Sticks to Their Buy Rating for Legend Biotech (LEGN)

Tipranks - Tipranks - Thu Apr 9, 9:08PM CDT

RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech on April 7 and set a price target of $62.00. The company’s shares closed yesterday at $17.99.

Easter Sale - 70% Off TipRanks

Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and Axsome Therapeutics. According to TipRanks, Timashev has an average return of 13.2% and a 48.00% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $54.71 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Legend Biotech’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $307.64 million and a GAAP net loss of $31.03 million. In comparison, last year the company earned a revenue of $186.52 million and had a net profit of $26.28 million

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).